文献速递神经重症与神经感染

1990-2016年全球、区域和国家脑膜炎负担:GBD 2016系统分析

Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
PubMed 文献 · Lancet Neurol · 2018-11-13

该研究基于GBD 2016,评估1990-2016年全球脑膜炎负担。负担与SDI密切相关,非洲脑膜炎带负担最重。病原谱发生转变,其他病因成为2016年死亡和发病首位,肺炎链球菌导致最多YLDs。

要点

  • 2016年其他病因是死亡和发病首位,肺炎链球菌导致最多YLDs。

核心结论

  • 全球脑膜炎负担仍高,进展显著落后于其他疫苗可预防疾病。
  • 需开发覆盖更广的疫苗、提高可负担性和接种率、改善诊疗可及性及对残疾幸存者的支持。
  • 持续的病原特异性监测对监测全球脑膜炎负担和趋势至关重要。

研究设计与样本

  • GBD 2016研究估算了肺炎链球菌、脑膜炎奈瑟菌、b型流感嗜血杆菌和其他病因四类脑膜炎负担。
  • 死因别死亡估计采用死因集成模型分析生命登记和口头尸检数据。
  • 发病率通过贝叶斯meta回归工具系统分析相关出版物及医院和索赔数据估算。
  • 采用meta回归拆分死亡和发病的病因比例,并应用长期损伤概率估算YLDs。
  • 评估负担指标与SDI的关系。

主要发现

  • 2016年非洲脑膜炎带十例病例和死亡最多的国家中占六席。

临床怎么用

  • 临床应关注非洲脑膜炎带等高负担地区的脑膜炎防控。
  • 重视肺炎链球菌等导致长期残疾的病原体,并加强幸存者康复支持。
  • 支持并参与病原特异性监测以指导疫苗和治疗规划。

局限性

  • 致病病因和危险因素仍存在大量不确定性。
  • 其他病因作为残余类别,其具体构成未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute meningitis has a high case-fatality rate and survivors can have severe lifelong disability. We aimed to provide a comprehensive assessment of the levels and trends of global meningitis burden that could help to guide introduction, continuation, and ongoing development of vaccines and treatment programmes. METHODS: The Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2016 study estimated meningitis burden due to one of four types of cause: pneumococcal, meningococcal, Haemophilus influenzae type b, and a residual category of other causes. Cause-specific mortality estimates were generated via cause of death ensemble modelling of vital registration and verbal autopsy data that were subject to standardised data processing algorithms. Deaths were multiplied by the GBD standard life expectancy at age of death to estimate years of life lost, the mortality component of disability-adjusted life-years (DALYs). A systematic analysis of relevant publications and hospital and claims data was used to estimate meningitis incidence via a Bayesian meta-regression tool. Meningitis deaths and cases were split between causes with meta-regressions of aetiological proportions of mortality and incidence, respectively. Probabilities of long-term impairment by cause of meningitis were applied to survivors and used to estimate years of life lived with disability (YLDs). We assessed the relationship between burden metrics and Socio-demographic Index (SDI), a composite measure of development based on fertility, income, and education. FINDINGS: Global meningitis deaths decreased by 21·0% from 1990 to 2016, from 403 012 (95% uncertainty interval [UI] 319 426-458 514) to 318 400 (265 218-408 705). Incident cases globally increased from 2·50 million (95% UI 2·19-2·91) in 1990 to 2·82 million (2·46-3·31) in 2016. Meningitis mortality and incidence were closely related to SDI. The highest mortality rates and incidence rates were found in the peri-Sahelian countries that comprise the African meningitis belt, with six of the ten countries with the largest number of cases and deaths being located within this region. Haemophilus influenzae type b was the most common cause of incident meningitis in 1990, at 780 070 cases (95% UI 613 585-978 219) globally, but decreased the most (-49·1%) to become the least common cause in 2016, with 397 297 cases (291 076-533 662). Meningococcus was the leading cause of meningitis mortality in 1990 (192 833 deaths [95% UI 153 358-221 503] globally), whereas other meningitis was the leading cause for both deaths (136 423 [112 682-178 022]) and incident cases (1·25 million [1·06-1·49]) in 2016. Pneumococcus caused the largest number of YLDs (634 458 [444 787-839 749]) in 2016, owing to its more severe long-term effects on survivors. Globally in 2016, 1·48 million (1·04-1·96) YLDs were due to meningitis compared with 21·87 million (18·20-28·28) DALYs, indicating that the contribution of mortality to meningitis burden is far greater than the contribution of disabling outcomes. INTERPRETATION: Meningitis burden remains high and progress lags substantially behind that of other vaccine-preventable diseases. Particular attention should be given to developing vaccines with broader coverage against the causes of meningitis, making these vaccines affordable in the most affected countries, improving vaccine uptake, improving access to low-cost diagnostics and therapeutics, and improving support for disabled survivors. Substantial uncertainty remains around pathogenic causes and risk factors for meningitis. Ongoing, active cause-specific surveillance of meningitis is crucial to continue and to improve monitoring of meningitis burdens and trends throughout the world. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018. PMID: 30507391. doi:10.1016/S1474-4422(18)30387-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。